^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | Tevimbra (tislelizumab-jsgr) (PD1 inhibitor) + ociperlimab (BGB-A1217) (TIGIT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Excerpt:
...Cohort 1: stage IV squamous NSCLC Cohort 2: stage IV non-squamous NSCLC Cohort 3: stage IV squamous or non-squamous NSCLC with PD-L1 positive....
Trial ID:
Source:
Title:
1020MO - AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity
Published date:
10/16/2023
Excerpt:
In 2L therapy of advanced ESCC pts with PD-L1 TAP ≥10%, O+T showed tolerable safety profile and trend toward better ORR, but similar PFS vs. P+T.
Trial ID:
Source:
Title:
1533P - Advantig-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (CT) in patients (pts) with metastatic oesophageal squamous cell carcinoma (ESCC) and oesophageal adenocarcinoma (EAC)
Published date:
10/16/2023
Excerpt:
Treatment-naïve adult pts with histologically/cytologically confirmed metastatic ESCC (C6) or EAC (C7) were enrolled. Pts received the RP2D of OCI + TIS with cisplatin + 5-fluorouracil/paclitaxel until disease progression, intolerable toxicity, or consent withdrawal....ORRs by biomarker subgroups: C6, 100% in pts with PD-L1 tumor area positivity (TAP) score ≥10% (n=4) vs 76.9% in pts with PD-L1 TAP <10% (n=13); 80.0% in pts with TIGIT IC score ≥5% (n=10) vs 87.5% in pts with TIGIT IC <5% (n=8).
Secondary therapy:
paclitaxel; cisplatin; 5-fluorouracil
Trial ID:
